News

Press Releases

AlveoGene Provides Latest Company Update

19/12/2025

December 19, 2025 – Oxford UK After a year of steady progress, AlveoGene is pleased to provide an update on the progress of its pipeline of inhaled gene therapy development

ATS 2025 Keynote Shares Exciting Progress in Gene Therapies Using AlveoGene’s InGenuiTy® Platform in Cystic Fibrosis – and beyond!

28/05/2025

Delivering the Monday 20 May Keynote Address for the ATS 2025 International Conference, Professor Eric Alton, MD, lead of the UK Respiratory Gene Therapy Consortium (GTC) and Co-Founder of AlveoGene,

Update on 2025 Development Progress

24/04/2025

Oxford (UK) Since extending our seed financing round earlier this year, the first 4 months of 2025 have seen AlveoGene make good progress in generating world leading pre-clinical data sets

AlveoGene on Biotech TV

24/04/2025

David Hipkiss, Executive Chair of AlveoGene had the great pleasure of talking with Amy Brown of BioTech TV at BioTrinity 2025 in London and outlines how we are using our

AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives Orphan Drug Designation from FDA for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

03/12/2024

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survival Highly encouraging preclinical data highlight the

AlveoGene Receives Rare Pediatric Disease Designation (RPDD) from FDA for AVG-002, its Novel, Inhaled Gene Therapy for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

15/11/2024

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants Clinical estimates for SP-B deficiency have an incidence of 1 in 1 million live

Events

JPM Week 2026 and RESI San Francisco

Executive Chair, David Hipkiss, will be attending JPM 2026 week in San Francisco week beginning 12th January 2026 meeting investors and partners regarding the latest developments and progress of the AlveoGene pipeline of inhaled gene therapy product candidates targeting rare respiratory diseases enabled by AlveoGene’s InGenuiTy® platform.

He will be attending the main JPM led symposium in The Westin on Union Square and RESI which takes place in at the Marriott Marquis San Francisco (780 Mission St, San Francisco, CA 94103).

Please reach out to request a meeting at david.hipkiss@alveogene.com